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Keratomed epidermal tissue from normal individuals and 
from the lesional and non-Jesional skin of psoriasis patients 
served as source materials for the extraction, separation, and 
quantitation of eicosanoids that may be important to cuta-
neous function and pathophysiology. The eicosanoids 
were extracted in ethanol and buffer, partially purified on 
SEP-PAKs, separated by reverse phase microbore high-per-
formance liquid chromatography, and quantitated by radio-
immunoassay or integration of absorbency peaks obtained by 
high performance liquid chromatography. 
The involved areas from psoriasis patients contained a sta-
tistically significant seven- to 11-fold increase in the levels of 
A rachidonic acid is the precursor of several biologically potent compounds that may playa significant role in the initiation and/or maintenance of the psoriatic le-sion. Elevations in free arachidonic acid and certain eicosanoids in lesional epidermis in comparison to un-
involved areas were first reported in 1975 (1 J. A large increase in 
lesional1 2-HETE levels and small but significant increases in PGEz 
and PGF2• were detected. Increased concentrations of LTB4 [2-4], 
LTC4, and LTD4 [5J in fluids from lesional areas have been re-
ported. A significant quantity of 13-hydroxyoctadecadienoic acid, a 
non-eicosanoid product of 15-lipoxygenase, has also been reported 
in psoriatic lesions [6]. 
A number of investi gators have quantitated a limited number of 
arachidonic acid metabolites in psoriatic scale [5 ,6], in fluid s from 
abraded skin [2,3 ,5,6J or suction blisters [4] , and in cell s in culture 
[7 ,8) or dispersed cells [9J. 
In order to obtain a more complete picture of the changes that 
occur in the lipoxygenase pathways in diseases such as psoriasis, we 
developed a method to assay these components from an individual 
sa mple. In this report we have described the methodology in detail 
and have used a single keratome biopsy sa mple, HPLC and RIA 
technologies, to identify and quantitate one product of each of the 
Iipoxygenase enzymes that function within human epidermis. The 
keratomed biopsies contained suffi cient material to quantitate prod-
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Abbreviations: 
AA: Arachidonic ac id 
ACN: Acetonitri le 
BSA: Bovine serum albumin 
I1ETE: l1ydroxyeicosatetraenoic acid 
HPLC: High-performance liquid chromatography 
LT: Lcukorrienes 
RIA: Radioimmunoassay 
13-11000: 13 Hydroxyoctadecadienoic ac id 
leukotriene B4 , 13-hydroxyoctadecadienoic acid-like Conh 
pound, 15-hydroxyeicosatetraenoic acid compound and 12, 
hydroxyeicosa tetraenoic acid in comparison to normal sam, 
pIes and a three- to sevenfold increase in comparison to 
uninvolved tissue. The uninvolved areas contained 40% to 
100% increases in the levels of these compounds in compari, 
son to normal tissue; these increases were statistically signifi, 
ca nt except for 13-hydroxyoctadecadienoic acid-like com, 
pound . From a single keratome biopsy, m.ultiple eicosanoids 
can be separated and quantitated; in addition, levels before, 
durin g, and after therapy for psoriasis may be compared. ] 
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ucts of 5-lipoxygenase (LTB4), 15-1ipoxygel1ase (15-HETE), and 
12-lipoxygenJse (12-HETE) by RIA at several different dilutions ill 
the assay. Our method permits the monitoring of the levels of 
various eicosanoids during therapy. This technology is not only 
relevant to psoriasis but ca n be used to study eicosanoid metabolislll 
in severa l skin diseases. 
MATERIALS AND METHODS 
Chemicals HPLC standards were obtained from the following 
sources: PGEz , PGF2" and PGD2 from The Upjohn Co. (Kalama-
zoo, MI); 5-HETE, 12-HETE, 15-HETE, 8-HETE, 9-HETE, and 
I1 -HETE from Cayman Chemica ls (Ann Arbor, MI); arachidonic 
acid from Nu-Chek Preps (Elysian, MN); 13-hydroxyoctadeca-
dienoic acid (13-HODD) from Oxford Biochemicals Research Inc. 
(Oxford, MI); LTB4 , LTC., and LTD4 were gifts from Merck-
Frosst (Pointe C laire, Quebec). 
Tritiated LTB4, 15-HETE, and 12-HETE were purchased frol1l 
N ew England Nuclear Research Products (Boston, MA) . HPLC 
grade acetonitri le, methanol, hexane, and water were purchased 
fro m Burd ick and J ackson Laboratories, Inc. (Muskegon, MI). Anti-
bodies to L TB4 were a gift from Merck, Sharp, and Dohme (Rah-
way, NJ) ; antibod ies to 12-HETE and 15-HETE were purchased 
fr0111 Seragen, Inc. (Boston, MA) . SEP-PAK C IS cartridges were 
purchased from Waters Associates (Milford, MA). Polypropylene 
pbsricware or siliconi zed glassware was used for all procedures. 
Biopsies After obta ining' informed co nsent, skin was infiltrated 
with 1% xy locaine without epinephrine. The epidermis was re-
moved with a Castroviejo keratome (Storz Instruments Co., St. 
Louis, MO) modifi ed with a variable speed motor (Kerr Manufac-
turers Inc. , Romulus, MI) and immediately frozen (within 7 sec) in 
liquid nitrogen. The frozen sa mples were stored at -70°C. For 
psoriatic patients 25 X 70 mm samples of both involved and unin-
volved epidermis were removed. For normal controls with no fam-
ily history of psoriasis, 50 X 70 mn1 samples were taken. 
Biopsy Components Biopsy samples have been monitored histo-
logica lly and contain the following . 1) Keratomed biopsies from 
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normal skin have 10 - 20% of their thickness as dermis which con-
tains fibroblasts and pap'illary capillaries. 2) Keratomed biopsies 
from uninvolved psoriasis skin contain the same components as 
normal biopsies but in addition contain absent to minimal inflam-
matory infiltrates. 3) Keratomed biopsies from lesional skin have 
10% - 20% of their thickness as dermis. The biopsies contain hyper-
plastic epidermal cells, dilated and tortuous capillaries, polymor-
phonuclear cells, mast cells, macrophages, and fibroblasts. 
Eicosanoid Extraction The -70 0 C biopsies were powdered 
under liquid nitrogen in a precooled mortar and pestle. While still 
froze n, the powder was transferred to a polypropylene centrifuge 
tube containing 4 ml of extraction solution (8 parts ethanol to 2 
parts 0.01 M phosphate buffer, pH 6.4, including tracer amounts of 
tritiated L TB4, 15-HETE, and 12-HETE). The extraction solution, 
which denatures enzymes, prevented further synthesis or hydrolysis 
of the eicosanoids. 
The samples were stirred on ice for 30 min with a magnetic 
stirrer, fo ll owed by centrifugation at 2500 X g for 10 min. The 
supernatant fraction was removed and saved. The pellets were re-
extracted for an additional 30 min with 2 ml of ethanol: 
methanol: buffer (4: 4: 2) and centrifuged again, as before. The su-
pernatant fraction was removed and combined with previous super-
natant. Then, the alcohol concentration was decreased to 15% by 
adding buffer (pH 5.4). An aliquot was removed so that recoveries 
could be determined at various steps and for a fina l recovery at the 
RIA step. 
The combined supernatant fractions were partially purified as 
follows: SEP-PAK cartridges conditioned with 3 X 10 ml of meth-
anol alternating with 3 X 10 ml of water [4] were equilibrated with 
5 ml of 0.01 M phosphate buffer pH 5.4 containing 0.02 M EDT A. 
The combined supernatant fraction was applied to the SEP-PAKs, 
washed with 7 m l of hexane, and the eicosanoids eluted with 5 m l 
of methyl formate and 4 ml of methanol. Aliquots of the initial 
sample and of eac h of the four fractions were counted to determine 
recovery. 
The methyl formate and methanol fractions were evaporated to 
dryness under a stream of nitrogen. The residues were suspended in 
200 J.lI of methanol and fi ltered through Millipore HV fi lters into 
si liconized glass microvials. The sa mples were evaporated under 
nitrogen to dryness and resuspended in a final volume of 15 J.lI of 
ace tonitrile and 15 J.ll of water acidified to pH 3.9. 
Eicosanoid Separation A Hewlett-Packard 1090 M unit equip-
ped with a ternary solvent system, diode array detector, and 9133H 
storage disk was used to separate the eicosanoids. Twenty micro-
liters of each sample was inj ected onto a Hewlett-Packard CIs-ODS 
microbore column (100 mm X 2.1mm). A flow rate of 0.3 mlj min 
at a temperature of 38 ° C was used throughout the 30-min ana lysis. 
The eicosanoids were separated by modification of the method of 
Van Rollins et al [10] . The initial solvent consists 000 parts aceto-
nitri le and 70 parts water containing 0.2% phosphoric acid adjusted 
to a pH 3.9 with ammonium hydroxide. After 6 min of isocratic 
elution an acetonitri le gradient was initiated th at reached 50% at 
15 min. During the next 5 min the acetonitrile concentration was 
increased to 55% followed by an increase to 85% during the next 
3 min. At 25 min the acetonitri le concentration was returned to 
65% to prevent precipitation of ammonium phosphate at high ace-
tonitrile concentrations and still cl ea n the column of non-eicosan-
oid lipids. 
The effluent from the HPLC was split such that 75% was di-
verted to a fractio n collector programmed for 30 sec fractions and 
25% of th e flow was diverted into a Radiomatic HS flow-through 
scinti llation counter and mixed with scinti ll ation fluid at a flow rate 
of 1.2 ml/min. The cell volume of the scintillation counter is 
0.5 ml. 
The 30-sec fractions corresponding to the L Ts and HETEs were 
evaporated to dryness under a stream of nitrogen. The residues were 
resuspended in 200 ttl of an appropriate buffer. Samples were taken 
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for radioimmunoassay quantitation and for counting the recovery of 
each eicosanoid. 
Radioimmunoassays For the HETE RIAs, the samples were 
assayed at 3 dilutions in 0.01 M phosphate buffer pH 7.6, 
0.9% N aCI, 0.1 % BSA or gelatin and 0.1 % sodium azide. Tritiated 
12-HETE or 15-HETE (8000 cpm/ tube) was added as labeled anti-
gen. Tota l volume of the assay was 300 J.ll. The standard curve 
ranged from 10 to 1000 picograms per tube. The binding was initi-
ated by th e addition of specific antibody. We determined that the 
15-HETE antibody cross reacts 0-5% with 12-HETE and 7% with 
13-HODD. The 12-HETE antibody cross reacts 0.3-2% with 15-
HETE, 0.1 % with L TB4, and 0.5% with 5-HETE. 
After the samples were incubated for 2 h at room temperature, 
the assay was terminated with the addition of 700 J.lI of dextran-
coated charcoal that had been stirred on ice for 15 min prior to use. 
All samples were kept on ice for 10 min, then centrifuged at 
2500 X g for 10 min. The supernatant fractions were transferred to 
scintil lation via ls, 7 ml of Amersham ACS cocktail were added, and 
the samples were counted in a Packard liquid scintillation counter. 
For L TB4 the samples were assayed as a single ' dilution for the 
norma l biopsies because the amount present in the samples was too 
sma ll for mu ltiple determinations. For the psoriatic samples, two 
dilutions were llsed for the uninvolved biopsies and three dilutions 
for th e involved biopsies. The tubes on either side of the fractions 
pooled for L TB4 determinations were combined and assayed as a 
background subtraction to correct for any interfering material 
eluted in th e fractio!ls containing LTB4 • The buffer contained 
0.02 M phosphate pH 7.2, 0.9% N aCI, 0.02% sodium azide, and 
0.2% BSA. The double antibody procedure of Rokach [11] was 
fo llowed with sli ght modification as follows. The standard curve 
ranged from 50 - 1600 picograms per tube. Tritiated L TB4 
(8000 cpm/ tube) was added as labeled antigen and normal rabbit 
serum as carrier. The LTB4 specific antibody (cross-reacts 6% with 
5-trans LTB4 and 2% with OH-LTB4) was added to initiate the 
binding and the samples (500 pI total volume) were incubated for 
2 h at 4 ° C. Goat anti-rabbit antibody (500 J.l1) was then added and 
the incubation continued for an add itional 18-20 h at 4°C. The 
binding was terminated by centrifugation for 10 min at 5000 X g. 
The pellet was washed twice with phosphate buffered saline and 
then dissolved in SOD It! of 0.1 % sodium dodecyl sulfate in 0.1 N 
N aOH. The dissolved pellet was transferred to a scintillation via l; 
theassay tube was rinsed with 250 J.ll of water which was added to 
the sample. Seven milliliters of ACS cocktail were added and the 
vial counted in a liquid scintillation counter. 
Data Bases The epidermal biopsies were weighed on a balance 
whi le frozen prior to grinding to determine the wet weight value of 
the sample. Proteins were determined by the method of Lowry et al 
[1 2] with bovine serum albumin as standard. DNA was determined 
by the method of Burton [13] usin g salmon sperm DNA as standard . 
Statistical Analysis The mean and standard error of the mean was 
determined for each series of sampl es. A two-tailed Student's t-test 
for paired data was used to analyze involved versus uninvolved 
sa mples. An unpaired, two-tailed Student's t-test was used for the 
analys is of normal versus uninvolved or involved samples. 
RESULTS 
The ch romatogram depicted in Fig 1 is typical of the eicosanoid 
sepa ration achieved when standards are llsed to check the system at 
th e start of eac h series of analyses. The prostaglandins PGF:z:., PGE2 , 
and PGD2 were eluted during the isocratic portion, the first 6 min 
of the run, with an acetonitrile concentration of 30%. The leuko-
trienes L TC4 , LTD 4, and L TB4 were eluted as the concentration of 
acetonitrile was increased 20% over a 9-min period. The mono-
HETEs and 13-HODD were eluted as the ace tonitrile concentra-
tion was increased to 55% over a 5-min period . A greater separation 
of 13-HODD, 15-HETE, 12-HETE, and 5-HETE can be obtained 
(wider peaks were the result) if the acetonitril e concentration re-
mained at 50% for 10 min before increasing the acetonitril e to 80%, 
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Figure 1. RP-Chromatogram of eicosanoid standards. Coll/l1l1l: Hypersil 
ODS (100 X 2.1 mm); flow rate 0.3 ml/min. The UV detector was set at 
192 nm from 0 - 9.5 min, at 280 nm from 9.5 - 17 min, 235 nm from 17 -
25 min, and 210 nm from 25 - 30 min. Temperature was 37 C. 
the concentration required to elute fatty acids such as arachidonic 
acid. All the compounds of interest were eluted within 25 min of 
the initial injection onto the HPLC column. 
Because the HP-1090 is equipped with a diode array detector, the 
spectrum of each standard was observed as it eluted from the co lumn 
and the information was stored on a Winchester disk for detailed 
evaluation at the end of the run . 
Figure 2 is a chromatogram obtained with an extract from a 
lesional area. The mono-HETE portion of the chromatogram con-
tains the most components. The insets in Fig 2 indicate the ultravio-
let spectrum of the compounds eluted in this portion of the cluo-
matogram; these are consistent with the spectra and RT of 
13-H 0 D D, 15-HETE, and 12-HETE. A large number of unknown 
compounds that absorb at 192 nm elute from the column in the 
early portion of the run and obscure prostaglandin peaks. 
Figure 3 shows the L TB. content of uninvolved and involved 
areas from 16 psoriatic patients and 24 volunteers with normal skin. 
The mean ± standard error of the mean (S.E.M.) for the normal, 
uninvolved, and involved samples are 1.3 ± 0.3, 2.4 ± 0.5, and 
11.0 ± 3.2 pg/,ug DNA, respectively. There is an 85% increase 
(p = 0.05) in LTB. levels in the extracts from uninvolved versus 
normal tissue and a 746% increase (p = 0.001) in L TB.levels in the 
extracts from involved versus normal tissue. A 358% increase 
(p = 0.01) in LTB.levels in the extracts from involved versus unin-
vo lved tissue was detected. Similar results were obtained if protein 
or wet weight was utilized as the data base (data not shown) . There 
is some overlap in the data points from the three groups; 8 out of 16 
biopsies from involved epidermis contained LTB. levels similar to 
those observed in normal or uninvolved tissue extracts . 
Figure 4 shows the RIA values obtained for 15-HETE levels in 
the extracts from normal, uninvolved, and involved keratome 
biopsy samples. The mean values are 2.0 ± 0.4, 4.3 ± 1.3 and 
25.5 ± 7.2 pg/,ug DNA, respectively. There is a 115% increase 
(p = 0.05) in the 15-HETE levels in extracts obtained from unin-
volved versus normal tissue and a 1175% increase (p < 0.001) in the 
extracts from involved versus normal tissues. For the extracts from 
areas of involved versus uninvolved, a 493% increase (p < 0.005) 
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Figure 2. RP-Chromatogram of invol ved psoriasis extract with absorption 
spectra consistent with the spectra of 13-HODD, 15-HETE, and 12-HETE. 
Details are the same as Fig 1. Arrows indicate retention times for the stan-
dards. 
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Figure 3. LTB. levels in normal human epidermis (N = 24), uninvolved 
psoriasis epidermis (N = ....! 6) as determined by RIA after separation of ex_ 
tracts by RP-HPLC. The X ± S.E.M. is given for each group. Theopw circles 
represent a data point for a single sample. 
was observed. Nine of the involved tissue sample values overlapped 
with those obtained for normal and uninvolved samples since one of 
the uninvolved samples was high. 
Figure 5 contains the RIA data obtained for 12-HETE levels 
extracted from normal, uninvol ved, and involved areas. The mean 
values for normal, uninvolved, and involved tissue samples are 
1.8 ± 0.4, 2.4 ± 0.5, and 18.5 ± 5.5 pg/ug DNA, respectively. 
There is a 33% increase (p = 0.10) in the 12-HETE concentrations 
in the extracts from uninvolved versus normal tissue and a 928% 
increase (p < 0.001) in the levels of 12-HETE in the involved 
versus normal tissue extracts. In a ~omparison of the extracts from 
involved to uninvolved samples, there is a 671 % increase (p = 0.01) 
in the 12-HETE in involved areas. However, in this series of analy-
ses there were two normal samples with unusually high values in 
comparison to the others and fell within the range of the involved 
biopsy samples. Five of the involved samples overlapped with the 
uninvolved and normal samples. 
Figure 6 shows the peak integration values from the HPLC for 
the 12-HETE levels. The mean values are 23.2 ± 3.8,35.8 ± 5.2, 
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Figure 4. 15-HETE levels in human epider!:,!is as determined by RIA after 
separation of extracts by RP-HPLC. T he X ± S.E.M. is given for each 
group. 
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Figure 5. 12-HETE levels in human epider,t!!is as determined by RIA after 
separation of extracts by RP-HPLC. The X ± S.E.M. is given for each 
group. 
and 384.5 ± 92 pg/,ug DNA, respectively, for the normal, unin-
volved, and involved areas. This represents an increase of 974% 
(p < 0.005) in 12-HETE levels in the involved versus uninvolved 
areas and an increase of 1557% (p < 0.005) for involved versus 
normal areas. There was a 54% increase (p < 0.05) for uninvolved 
versus normal areas. The 12-HETE level of one involved sample 
overlapped with the uninvolved samples. 
With linoleic acid as the substrate, 15-lipoxygenase forms 13-
HODD rather than 15-HETE. The results for 13-HODD-l ike 
compound are presented as peak integration values obtained by 
HPLC because an RIA is not currently available. 13-HODD-like 
compound is present in sufficient quantity to permit absorbency 
measurements. Figure 7 gives the data (pg/,ug DNA) for the ex-
tracts for normal, uninvolved, and involved keratome biopsies. The 
mean ± S.E.M. values for the extracts are 33.5 ± 1.7, 47.0 ± 3.4, 
and 373.3 ± 21.3, respectively. A statistically insignificant 40% in-
crease (p = 0.1) was determined for the 13-HODD-like compound 
levels in extracts from uninvolved versus normal samples. The in-
volved extracts showed a 1014% increase (p < 0.001) over normals 
in 13-HODD-like compound levels. Involved extracts had a 694% 
increase (p = 0.001) in 13-HODD-like compound levels over un-




















Figure 6. 12-HETE levels in normal human epidermis (N = 9). unin-
volved, and involved psoriasis epidermis (N = 9) as ~termined by peak 
integration of the componcnt during RP-HPLC. The X ± S.E.M. is given 
for each group. 
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Figure 7. 13-HODD-like compound levels in normal human epidermis 
(N = 15). and uninvolved and involved epidermis (N = 14) as.ictermined 
by pcak integration of the componcnts during RP-HPLC. Thc X ± S.E.M. 
is given for each group. 
14 involved samples overlapped with the normal and uninvolved 
samples. 
DISCUSSION 
The keratome biopsies provide sufficient material for th e analysis of 
the eicosanoids as well as determinations of protein content, DNA 
content, and wet weight for data bases. Approximately 7 sec are 
required to remove the epidermal strips, thus minimizing changes 
in eicosanoid levels. Any artifactual changes in eicosanoids during 
this period are assumed to be similar or proportional to in vivo 
levels . Increases in the cysteinyl leukotrienes have been demon-
strated after severe trauma in other tissues [14] but increases in L TB4 
have not been reported. 
The SEP-PAK partial purification removed unwanted lipids and 
salts extracted from the tissue that might interfere with the micro-
bore HPLC system or interfere with the subsequent RIA determina-
tions. This also permits the concentration of eicosanoids in a rela-
tively small volume and in a volatile solvent for further 
concentration prior to HPLC separation. 
All of the eicosanoids of interest were separated by HPLC within 
25 min on a 10 cm microbore reverse phase column with a flow rate 
of 0.3 ml/ min. The HPLC separation eliminates the problems re-
lated to antibody specificity in an RIA in most cases. For example, 
the eicosanoids are present in relatively small concentrations that do 
not permit extensive dilution prior to assay as a way of eliminating 
interfering materials in an RIA. In addition, despite the commercial 
avai labi lity of antibodies and antigens, cross-reactivity does occur 
and varies with different lots . Following HPLC separation, the 
purified eicosanoids were collected for quantitation by RIA, elimi-
luting many of the problems with interfering substances or cross-
reactivity of antibodies. 
Occasionally we observed compounds with retention times simi-
lar to L TB4 or L TC4, but the absorption spectra of these peaks were 
not consistent with a triene structure. A component with retention 
time and absorption spectra consistent with 13-HODD (presum-
ably 13-HODD itself) was frequently the largest component ob-
tained; this was particularly true of the extracts from involved areas. 
13-HODD-like compound has been quantitated by integration 
of the HPLC peaks. The compound does cross-react with some lots 
of antibody to 15-HETE and such antibodies may provide a second 
means of quantitating the 13-HODD. However, this possibility 
presents an obvious problem in accurate quantitation of 15-HETE. 
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In sufficient separation of 13-HODD from 15-HETE fractio ns may 
g ive fa lsely high levels of 15-HETE. The 13-HODD and 15-
HETE retention times are separated by 0.8 to 1 min in this series of 
experiments; thus th e overlap should be minimal. 
The 12-HETE fractions obtained by HPLC may contain 8-
HETE because the retention times for the two compounds on ly 
differ by 0. 2 min by reverse phase HPLC. In this study the 12-
HETE fract ions were not furth er separated by straight ph ase HPLC 
to remove 8-HETE that might have been present. In more recent 
studi es, the re-chromatographin g of the 12-HETE peaks using 
straight phase HPLC, 85 - 90% of the 12-HETE peak is retained as 
12-HET E in the involved and uninvolved psoriatic biopsies. The 
co ntrol biopsies retain 96% of the 12-HETE peak as 12-HETE. 
The levels of 12-HETE first published by us in 1975 [1 J showed 
an 80-fold increase in 12-HETE concentrations in involved 
(4061 ± 2052 pg/m g tissue) versus uninvolved (49 ± 7 pg/mg tis-
sue) areas. The m agnitude of the difference cou ld be attributed in 
part to two samples that were six- to tenfold hi gher than the mean of 
th e other five invo lved samples (900 ± 148 pg/mg tissue). The 
data in this paper based on RIA va lues or HPLC integration values 
show a seven- to ninefold increase in the 12-HETE levels in the 
involved versus uninvolved samples. The mean value for involved 
sampl es based on peak integration is 465 pg/mg tissue or about 
one- half the GC-MS values (900 pg/mg tissue) in our early report. 
The uninvolved leve ls (50 pg/ m g tissue) based on integration of 
12-HETE peaks are quite comparable to those reported in our origi-
nal publication (49 pg/mg tissue). 
The 1 2-H~TE antibody used in the RIA was raised against 12-S-
HETE produced by platelets. Recently, Woollard [1 5J has reported 
that psoriatic scale contains primaril y 12-R-HETE rather than 
12-S-HETE. Depend ing on the cross-reactivity of th e 12-R-HETE 
with the 12-S-HETE antibody, the RIA could underestimate the 
amount of 12- HETE present in th e samples. T he availability of pure 
12-R-HETE and 12-S-HETE has partially answered the variation 
in th e quantitated values for 12-HETE by HPLC pea k integration 
versus RIA values. Testing of the most recent 12-HETE antibodies 
indicates .that there is about a 10% cross-reactivity with 12-R-
HETE. Thus the currentl y available antibodies are relat ive ly spe-
cific for 12-S-HETE. The 12-R-HETE versus 12-S-HETE in psor-
iatic lesions needs further separation via Pirkle columns or 
derivati zation to co nfirm th e stereochemistry of the compound iso-
lated from the lesions. The values obtained for 12-HETE in this 
study by integration of the HPLC peaks are more consistent with 
th e values obtained by GC-MS than are the RIA values in this study. 
The L TB4levels in the keratomed biopsies from psorias is patients 
in this study were 1 - 8 ng/biopsy in contrast to normal or unin-
volved areas of less than 1 ng/biopsy. Expressed in terms of wet 
weight the involved areas average 20 pg/mg tissue, whereas in nor-
m al and uninvolved epidermis 3-4 pg/m g tissue was detected . The 
source of the L TB4 detected in lesional areas may originate from 
neutrophils. N eutrophils produce 2 - 14 ng LTB4 per 106 cells in 
5 min [16,17J . These ce ll s are present in the psoriatic lesion. Sam-
ples obtained from chamber fluid above an abraded involved psoria-
sis area gave a mea n value of 105 pg LTB4!ml fluid [2] . In a sim il ar 
study th at used suctio n blister fluid from e ight lesional areas a mean 
va lue of 649 pg LTB4/ml of fluid was obtained [4]. Recently the 
L TB4 levels in rabbit skin were given as 1.3 ng!8 mm punch biopsy 
in non-challenged state and the level s were increased to 7.5 ng after 
injection of arachidonic acid [1 8]. Lun g and tracheal tissues contain 
10 - 15 pg LTB4/mg tissue [1 9]. Thus the level s of LTB4 obtained 
in this study are in the range of those obtained in other tissues. 
Other cell s, such as mast cells, which are present in the lesional 
areas probably do not contribute signifi ca ntly to th e eicosanoid de-
terminations. Mas t cells produced PGD2 , LTC4, LTD4, and 5-
H ETE. N one of these compounds were observed by HPLC. 
In this study the keratome strips from different lesions, from 
different sites, and at different times have been evaluated for eico-
sa noid leve ls. Some overlap in the levels occurred in the various 
categories, i. e., normal, uninvolved and involved psorias is but the 
mea n levels in most cases are significantly different. With this 
methodo logy eicosa noids can be monitored before, during, and 
THE JOUltNAL OF lNV ESTlGATlVE DERMATOLOGy 
after therapy to determine shifts in concentration versus improve_ 
ment of the remaining lesions. Such information may provide a 
mea ns of assessing the significa nce of elevated eicosanoids in the 
initiation and/or maintenance of the psoriatic lesion. 
We wish to tllOllkjo!1Il ForllllleJor his expert teellllieo! ossistollee, CorolY" Peterse" 
Jor doillg the kerato llle biopsies oj the psoriatic olld ,wrlllol "o/l/lIleers, alld Cathy 
Yoh e alld Wmdy Marsh Jar typillg the lIIolll/script. 
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